CLCS
Cell Source, Inc.
Key Financials
Operating Income
$-3840244
↑ 11.2%
Net Income
$-4512642
↑ 15.2%
EPS (Diluted)
$-0.14
↑ 17.6%
Shareholders' Equity
$-18537836.00
↓ 18.7%
Total Liabilities
$18.8M
↑ 19.1%
Total Assets
$286500.00
↑ 46.8%
Cash & Equivalents
$222665.00
↑ 139.2%
Long-term Debt
$50000.00
N/A
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/14/2026 | View on SEC |
| 10-K | 4/7/2026 | View on SEC |
| 15-12G | 7/16/2025 | View on SEC |
| 8-K | 6/27/2025 | View on SEC |
| NT 10-K | 3/28/2025 | View on SEC |
| 10-Q | 11/14/2024 | View on SEC |
| 10-Q | 8/19/2024 | View on SEC |
| NT 10-Q | 8/14/2024 | View on SEC |
| 10-Q | 7/29/2024 | View on SEC |
| 10-K | 6/24/2024 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CLCS |
| Company Name | Cell Source, Inc. |
| CIK | 1569340 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 646-612-7554 |